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LETTERS TO THE EDITOR
Contrast Media: Is There a Preferable Agent
for Coronary Interventions?
The recent article by Grines et al. (1) serves to reawaken the age-old
discussion regarding adverse events, including thrombotic complica-
tions potentially related to contrast media. This phenomenon was
described by Robertson in 1987 (2), when he observed blood clot
formation in angiographic syringes filled with a mixture of contrast
medium and blood that were left stagnant for 30 min. Additional in
vitro scientific evaluations have been subsequently undertaken. These
data indicate that low osmolar nonionic contrast media confers less of
an anticoagulant effect than ionic contrast media (3). Nonionic con-
trast reduces platelet surface charge, binds fibrinogen and modifies
fibrin clot formation. Ionic contrast media have been found to produce
more profound effects on fibrin fiber formation at low levels, but
similar effects are observed at typical in vivo doses. There appears to be
no inherent thrombogenicity of low osmolar nonionic contrast media.
Granger et al. (4) reported in vivo data on nonionic contrast agents
indicating that both ionic and nonionic contrast cause alteration in
fibrin assembly that may be difficult to lyse when these thrombi occur
(4).
Large-scale clinical trials on the thrombotic potential of nonionic
contrast in the setting of diagnostic cardiac catheterization have
demonstrated no increase in the incidence of major thrombotic
complications. A study of 8,517 consecutive patients undergoing
diagnostic cardiac catheterization reported the incidence of throm-
botic complications to be 0.18% (5). This figure compares favorably to
large-scale trials describing thrombotic complications with ionic con-
trast media.
The prospective trial performed by Grines et al. has several
limitations. The most important of which is recognized by the authors.
The study involved a relatively small cohort of patients, and therefore
all statistical significance levels of the prespecified end points were
either borderline or not significant. Of the three primary end points,
angiographic evidence of intermittent patency, thrombus formation or
distal embolization, only Thrombolysis in Myocardial Infarction
(TIMI) flow that decreased by one or more grade was able to achieve
borderline significance, with a p value of 0.04. Neither of the other two
primary end points were statistically significant. Similarly, for the
secondary end points of recurrent ischemia and need for revascular-
ization, neither reached statistical significance. Early reocclusion or
restenosis requiring angioplasty was only of borderline significance,
with a p value of 0.06.
Although, patients were more likely to undergo recatheterization
in the group receiving low osmolar ionic contrast, recurrent pain was
noted equally in the two groups. There was no increase in the
incidence of early reocclusion, restenosis requiring reangioplasty or
documented abrupt closure. The authors undertook several subgroup
analyses of the data that were not prespecified end points of the trial.
Using this strategy, they uncovered several univariate factors more
prevalent in a nonionic contrast group. These included symptoms of
angina, angina at rest and reduced need for subsequent bypass surgery.
If additional univariate comparisons are made, then statistical correc-
tion for multiple comparisons should be applied to these data. When
this correction is used, none of the variables are statistically significant.
Why was a multivariate analysis performed?
Of additional concern is the higher dose of maintenance heparin
infusion after precutaneous transluminal coronary angioplasty in the
group receiving low osmolar nonionic contrast medium. Recent data
suggest that heparin stimulates fibrinogen receptor activation and
alpha degranulation of platelets and may also induce immunoglobulin
G antibodies that cause platelet activation and thrombocytopenia
(6,7). Thus, the concern is the additional dose and duration of heparin
therapy in the nonionic contrast group may be an important contrib-
uting factor to the adverse events that were observed. The use of
glycoprotein IIb/IIIa inhibitors was not available during this trial but is
primarily indicated for the patient cohort that was evaluated. What
effect this potent inhibitor of platelet aggregation would have on these
results is unknown.
Although the authors should be commended for their pilot work,
additional larger scale, prospective, randomized trials will be necessary
to further evaluate this question. The preponderance of available
experimental and clinical data fail to indicate that low osmolar ionic
contrast media are the preferable agent in the setting of coronary
angioplasty.
CHARLES J. DAVIDSON, M.D.
Northwestern University Medical School
Cardiac Catheterization Laboratory
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Reply
Davidson raises several issues in response to our randomized trial (1)
that demonstrated that ionic contrast is superior to nonionic contrast
in reducing the risk of ischemic complications after coronary angio-
plasty:
1. Davidson references his publication in which retrospective
review of patients undergoing diagnostic catheterization showed no
difference in thromboembolic complications when ionic and nonionic
agents were compared. We acknowledged this in our original discus-
sion; however, we noted that “It was an observational study limited to
patients undergoing only diagnostic catheterization, a procedure asso-
ciated with a low incidence of thromboembolic events.” Given the low
frequency of events in patients undergoing elective catheterization, a
randomized trial of tens of thousands of patients may be necessary to
show a significant difference.
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2. Davidson states that the secondary end points of recurrent
ischemia and need for revascularization did not achieve statistical
significance. Recurrent ischemia, defined as chest pain with electro-
cardiographic changes prompting catheterization was significant at a
level of p 5 0.02. Moreover, revascularization by either percutaneous
transluminal coronary angioplasty (PTCA) or coronary artery bypass
graft surgery was significant, with a p value of 0.04.
3. “The authors undertake several subgroup analyses of the data
which were not prospective endpoints of the trial.” It should be
pointed out that some of the subgroup analyses were requested by
reviewers of the report. In addition, the examples given (angina,
angina at rest and the need for revascularization) were in fact
secondary end points of the trial.
4. “An additional concern is the higher dose of maintenance
heparin infusion after PTCA in the group receiving low osmolar
nonionic contrast media.” There was no difference in the dose or
duration of post-PTCA heparin administration between ionic and
nonionic groups.
5. We agree with Davidson that larger scale, prospective, random-
ized trials would be helpful and pointed that out in the discussion of
our publication.
6. Davidson questions what effect glycoprotein IIb/IIIa inhibitors
would have on our results. Given the expense ($1,300/dose), it is not
reasonable to consider using ReoPro to “protect” against the throm-
botic potential of nonionic agents. Furthermore, the EPIC trial (2)
compared patients treated with ionic versus nonionic agents and
demonstrated a significant reduction in clinical events in the ionic
contrast group, irrespective of whether the patient was treated with
ReoPro (Table 1). In fact, the difference in clinical events comparing
ionic and nonionic agents is greater than the beneficial effect observed
of 7E3 over placebo. Likewise, in the RESTORE trial (3), in which
2,139 patients were randomized to receive placebo versus tirofiban,
nonionic contrast media increased the risk of ischemic events com-
pared with ionic agents.
The important question is, Why would anyone use nonionic
contrast preferentially over ionic agents? It is expensive, and there are
no documented clinical benefits in reducing renal failure or cardiac
events. The nuisance side effects (nausea and itching) sometimes
observed with ionic contrast can be prevented by pretreatment with
antihistamines. In addition to the in vitro, in vivo and observational
studies that demonstrated differences in clotting between ionic and
nonionic contrast, six randomized trials have been conducted in
patients undergoing PTCA (1,4–8). Five of the six studies concluded
that ionic contrast was superior to nonionic agents (Table 2). On the
basis of the available data, it is difficult to understand why any
interventional cardiologist would subject his or her patients to the
potential thrombotic risk of nonionic contrast agents.
CINDY L. GRINES, MD, FACC
Cardiac Catheterization Laboratory
William Beaumont Hospital
3601 West Thirteen Mile Road
Royal Oak, Michigan 48072
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Table 2. Randomized Trials of Ionic Versus Nonionic Contrast
Agents During Percutaneous Transluminal Coronary Angioplasty
Study (ref no.) Results
Grines et al. (1) 2 need for urgent recatheterization (p 5 0.02) and re-
PTCA with ionic agent (p 5 0.06)
Piessens et al. (4) 2 abrupt thrombosis with ionic agent (p 5 0.05)
Esplugas et al. (5) 2 abrupt thrombosis with ionic agent (p 5 0.005)
Morice et al. (6) 2 abrupt occlusion with ionic agent (p 5 0.05)
Bertrand et al. (7) 2 platelet deposition on guide wire with ionic agent
(p 5 0.005)
Lembo et al. (8) No difference between ionic and nonionic agents
PTCA 5 percutaneous transluminal coronary angioplasty; ref 5 reference;
2 5 decrease in.
Table 1. Effect of Contrast Agent on EPIC Results*
In-Hospital
Event Ionic Nonionic
%
Reduction p Value
In-lab closure 7 10 30 0.003
Q wave MI 0.7 1.9 63 0.018
Death 0.4 1.5 73 0.016
Placebo
7E3 Bolus 1
Infusion
%
Reduction p Value
Nonfatal MI† 8.6 5.2 39 0.013
Death† 1.7 1.7 0 0.96
*Data from Aquirre et al. (2). †Only 30-day events reported. EPIC 5
Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic
Complications; lab 5 catheterization laboratory; MI 5 myocardial infarction.
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